Katerina Bouchalova

Summary

Country: Czech Republic

Publications

  1. ncbi request reprint Lapatinib in breast cancer - the predictive significance of HER1 (EGFR), HER2, PTEN and PIK3CA genes and lapatinib plasma level assessment
    Katerina Bouchalova
    Laboratory of Experimental Medicine, Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University Olomouc and University Hospital Olomouc, Czech Republic
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 154:281-8. 2010
  2. doi request reprint BCL2 is an independent predictor of outcome in basal-like triple-negative breast cancers treated with adjuvant anthracycline-based chemotherapy
    Katerina Bouchalova
    Laboratory of Experimental Medicine, Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University, Hnevotinska 5, 775 15, Olomouc, Czech Republic
    Tumour Biol 36:4243-52. 2015
  3. doi request reprint High lapatinib plasma levels in breast cancer patients: risk or benefit?
    Magdalena Cizkova
    Laboratory of Experimental Medicine, Institute of Molecular and Translational Medicine, Palacky University and University Hospital Olomouc, Olomouc, Czech Republic
    Tumori 98:162-5. 2012
  4. doi request reprint Frequency of chromosome 17 polysomy in relation to CEP17 copy number in a large breast cancer cohort
    Vladimira Koudelakova
    Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University and University Hospital in Olomouc, Hnevotinska 5, 775 15 Olomouc, The Czech Republic
    Genes Chromosomes Cancer 55:409-17. 2016
  5. ncbi request reprint Triple negative breast cancer--current status and prospective targeted treatment based on HER1 (EGFR), TOP2A and C-MYC gene assessment
    Katerina Bouchalova
    Department of Paediatrics, Faculty of Medicine and Dentistry, Laboratory of Experimental Medicine, Palacky University and University Hospital, Olomouc, Czech Republic
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 153:13-7. 2009
  6. ncbi request reprint Triple negative breast cancer - BCL2 in prognosis and prediction. Review
    Katerina Bouchalova
    Laboratory of Experimental Medicine, Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University and University Hospital Olomouc, Hnevotinska 5, 775 15, Olomouc, Czech Republic
    Curr Drug Targets 15:1166-75. 2014
  7. doi request reprint Collagen triple helix repeat containing 1 protein, periostin and versican in primary and metastatic breast cancer: an immunohistochemical study
    Gvantsa Kharaishvili
    Department of Clinical and Molecular Pathology, Laboratory of Molecular Pathology, Institute of Molecular and Translational Medicine, Palacky University and University Hospital, Olomouc, Czech Republic
    J Clin Pathol 64:977-82. 2011

Collaborators

  • Marian Hajduch
  • Marek Svoboda
  • Bohuslav Melichar
  • Magdalena Cizkova
  • Vladimira Koudelakova
  • Radek Trojanec
  • Zdenek Kolar
  • Gvantsa Kharaishvili
  • Jana Vrbkova
  • Lakshman Varanasi
  • Sandra Donevska
  • David Friedecky
  • Miloslava Zlevorov√°
  • Lenka Radova
  • Karel Cwiertka
  • Anna Janostakova
  • Adriana Polynkova
  • Michaela Zezulov√°
  • Jan Bouchal
  • Giorgi Mgebrishvili

Detail Information

Publications7

  1. ncbi request reprint Lapatinib in breast cancer - the predictive significance of HER1 (EGFR), HER2, PTEN and PIK3CA genes and lapatinib plasma level assessment
    Katerina Bouchalova
    Laboratory of Experimental Medicine, Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University Olomouc and University Hospital Olomouc, Czech Republic
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 154:281-8. 2010
    ..However, only HER2 is currently used for therapy indications and new predictors for the treatment with lapatinib are sought...
  2. doi request reprint BCL2 is an independent predictor of outcome in basal-like triple-negative breast cancers treated with adjuvant anthracycline-based chemotherapy
    Katerina Bouchalova
    Laboratory of Experimental Medicine, Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University, Hnevotinska 5, 775 15, Olomouc, Czech Republic
    Tumour Biol 36:4243-52. 2015
    ..BCL2 expression analysis could facilitate decision making on adjuvant treatment in TNBC patients...
  3. doi request reprint High lapatinib plasma levels in breast cancer patients: risk or benefit?
    Magdalena Cizkova
    Laboratory of Experimental Medicine, Institute of Molecular and Translational Medicine, Palacky University and University Hospital Olomouc, Olomouc, Czech Republic
    Tumori 98:162-5. 2012
    ..The aim of the present study was to determine lapatinib plasma levels in breast cancer patients treated with lapatinib plus capecitabine...
  4. doi request reprint Frequency of chromosome 17 polysomy in relation to CEP17 copy number in a large breast cancer cohort
    Vladimira Koudelakova
    Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University and University Hospital in Olomouc, Hnevotinska 5, 775 15 Olomouc, The Czech Republic
    Genes Chromosomes Cancer 55:409-17. 2016
    ..3%, respectively). Our results suggest that chromosome 17 polysomy is a rare event found in <1% breast cancer cases and that polysomy of other chromosomes frequently occurs with chromosome 17 polysomy. © 2016 Wiley Periodicals, Inc. ..
  5. ncbi request reprint Triple negative breast cancer--current status and prospective targeted treatment based on HER1 (EGFR), TOP2A and C-MYC gene assessment
    Katerina Bouchalova
    Department of Paediatrics, Faculty of Medicine and Dentistry, Laboratory of Experimental Medicine, Palacky University and University Hospital, Olomouc, Czech Republic
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 153:13-7. 2009
    ..However, molecular targets and predictors for the treatment of triple negative breast carcinoma do not currently exist...
  6. ncbi request reprint Triple negative breast cancer - BCL2 in prognosis and prediction. Review
    Katerina Bouchalova
    Laboratory of Experimental Medicine, Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University and University Hospital Olomouc, Hnevotinska 5, 775 15, Olomouc, Czech Republic
    Curr Drug Targets 15:1166-75. 2014
    ..For this reason, search for markers that can predict the efficacy of chemotherapy in TNBC is a priority...
  7. doi request reprint Collagen triple helix repeat containing 1 protein, periostin and versican in primary and metastatic breast cancer: an immunohistochemical study
    Gvantsa Kharaishvili
    Department of Clinical and Molecular Pathology, Laboratory of Molecular Pathology, Institute of Molecular and Translational Medicine, Palacky University and University Hospital, Olomouc, Czech Republic
    J Clin Pathol 64:977-82. 2011
    ..It is an extracellular matrix protein which is also abnormally expressed in the tumour microenvironment. CTHRC1 has not been studied in breast cancer by immunohistochemistry...